Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Xiaomi Shares Jump on Europe EV Expansion Plan 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Anthropic IPO Marketing Expected to Start in Mid-October 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Add as a preferred source on Google
DURHAM, N.C., Feb. 22, 2018 -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that it will host a live conference call and audio webcast on Thursday, March 1, 2018 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2017, and to provide a business overview.
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 1153769. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and Compound Library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus to enter clinical testing. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
Michelle LaSpaluto
919-972-7115
[email protected]
or
Will O’Connor
Stern Investor Relations
[email protected]
212-362-1200
Media:
Becky Vonsiatsky
W2O Group
[email protected]
413-478-2003
